Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
31 results
D3.370 - Three cases of erdosteine-induced delayed drug hypersensitivity
D3.373 - Non-immediate Hypersensitivity Reactions To Both Penicillin and Aminopenicillin and Diagnostic approach – A Real Life Retrospective Study
D3.372 - Rapid Intramuscular Penicillin Desensitization: A Promising Future
D3.374 - Recall urticaria to dalteparin sodium in a patient with previous systemic reaction to nadroparin calcium
D3.375 - Delayed-Type Drug Reactions in Pediatric Patients: Clinical Features and Management
D3.376 - Drug Allergy Related to Chemotherapy and Premedication: Anaphylaxis Induced by Carboplatin and Methylprednisolone
D3.377 - Causes of a morbilliform rash: when the most frequent answer is not
D3.378 - Drug hypersensitivity in children in a frontline setting: interim results of a pilot epidemiological project
D3.379 - Varenicline´s DRESS Syndrome
D3.380 - The Most Serious Threat in Perioperative Hypersensitivity Reactions (PHRs): Neuromuscular Blocking Agent (NMBA) Hypersensitivity and Cisatracurium as a Safe Haven in the Setting of Cross-Reactivity
D3.381 - The paradox of treatment: H1-antihistamines-induced urticaria in a patient with chronic spontaneous urticaria
D3.382 - Safety and outcomes of penicillin desensitization during pregnancy: experience from a tertiary referral center
D3.383 - Delayed T-cell–mediated hypersensitivity to dimethyl fumarate: clinical presentation and diagnostic considerations
D3.384 - Assessment of the role of Rapid Drug Desensitization to treat cancer patient with infusion-related allergic reactions. Italian experience
D3.418 - A Phase 1b Study of Lesigercept, a Long-acting High-affinity IgETrap-Fc Fusion Protein: Safety, Tolerability, PK, and PD in Atopic Healthy and Allergic Subjects
D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset
D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study
D3.421 - Real-world Effectiveness and Safety of Lanadelumab Treatment in Patients With Hereditary Angioedema: The 12-Month Interim Analysis of a Polish, Prospective, Multicenter, Observational Study (CHOPIN)
D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes
D3.423 - Lanadelumab treatment is effective and safe in patients with Factor XII associated cold-induced autoinflammatory syndrome: results from an open-label proof-of-concept study
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download